Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model

The broadly neutralizing antibody (bNAb) VRC01, capable of neutralizing 91% of known human immunodeficiency virus type 1 (HIV-1) isolates in vitro, is a promising candidate microbicide for preventing sexual HIV infection when administered topically to the vagina; however, accessibility to antibody-b...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Zhao, Chunxia, Gunawardana, Manjula, Villinger, Francois, Baum, Marc M., Remedios-Chan, Mariana, Moench, Thomas R., Zeitlin, Larry, Whaley, Kevin J., Bohorov, Ognian, Smith, Thomas J., Anderson, Deborah J., Moss, John A.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2017
Sujets:
Pharmacology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5487619/
https://ncbi.nlm.nih.gov/pubmed/28416548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02465-16
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires